Skip to main content
. 2022 Jun 2;14(6):1193. doi: 10.3390/pharmaceutics14061193

Table 3.

Research of inhaled siRNA formulations for chronic respiratory diseases.

Disease Target Administration Delivery System Ref.
Asthma GATA3 Inhalation Tf-Mel-PEI [40]
Asthma Chil3, Chil4 Intratracheal
Administration
HMG-OR [43]
Asthma VDBP Intra-tracheal
instillation
DEXA-PEI [44]
Asthma c-Kit Intranasal
administration
Modified siRNA [45]
Asthma SOCS3 Intranasal
administration
Naked siRNA [46]
Asthma Syk Intranasal
administration
Naked siRNA [47]
COPD RIP2 Intratracheal
administration
Naked siRNA [48]
COPD RPS3 Intratracheal
administration
Naked siRNA [49]
COPD/ILD Cytokine
Signaling
Nasal instillation CaP-PLGA [41]
COPD MAP3K19 Intratracheal
administration
Naked siRNA [50]

Notes: Tf, transferrin; Mel, melittin; PEI, polyethyleneimine; HMG, high mobility group; OR, oligoarginine; DEXA-PEI, dexamethasone-conjugated polyethyleneimine; CaP, calcium phosphate nanoparticles; PLGA, poly(lactic-co-glycolic acid).

HHS Vulnerability Disclosure